Abstract
Pergolide, an ergot dopamine agonist with high affinity for dopamine receptors, was first approved as an adjunct to levodopa therapy in patients with Parkinson’s disease (PD) in the United States in 1988. Later, the efficacy of pergolide monotherapy was established for patients with early-stage PD. Since the 2000s, clinicians learned that idiopathic fibrosis, particularly of the heart valves, can be caused by long-term treatment with ergot dopamine agonists. Consequently, pergolide was withdrawn from the US market in 2007. The underlying mechanism for the development of fibrosis was thought to be associated with activation of serotonin receptor subtype 5-HT2B. A meta-analysis reported that the risk of valvular regurgitation increased by 3.05 times in patients with PD taking pergolide. In addition, the mean cumulative dose of pergolide could be positively associated with the odds ratio concerning valvular regurgitation. Nevertheless, pergolide is still used as a treatment for PD in some countries but is considered as a second choice when patients do not respond well to other parkinsonian drugs. The recommended dose for pergolide is up to 3 mg/day, and it should be judiciously used with regular echocardiography, chest X-rays, and urine and blood tests.
This is a preview of subscription content, log in via an institution to check access.
References
Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagù S, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology. 1999;53:573–9.
Bowsher RR, Apathy JM, Compton JA, Wolen RL, Carlson KH, DeSante KA. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma. Clin Chem. 1992;38:1975–80.
Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson’s disease. Cochrane Database Syst Rev 2000a;2:CD000236.
Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2000b;2:CD000235.
Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005;64:1450–1.
De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz. 2013;38:868–80.
European Medicines Agency. Ergot-derived dopamine agonists [Internet]. 2008. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Ergot_derived_dopamine_agonists/human_referral_000107.jsp
Japanese society of neurology. Treatment guidelines for Parkinson’s disease 2011 [Internet]. 2011.Available from: http://www.neurology-jp.org/guidelinem/parkinson.html
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.
Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry. 2007;19:523–30.
National institute for health and care excellence. Parkinson’s disease in adults [Internet]. 2017. Available from: https://www.nice.org.uk/guidance/ng71
Navan P, Findley LJ, Undy MB, Pearce RK, Bain PG. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol. 2005;12:1–8.
Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2006;21:343–53.
Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord. 1994;9:40–7.
Pohanka M, Kanovský P, Bares M, Pulkrábek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson’s disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord. 2005;11:509–12.
Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280–6.
Rasmussen VG, Østergaard K, Dupont E, Poulsen SH. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord. 2011;26:801–6.
Stowe R, Ives N, Clarke CE, Deane K, Hilten V, Wheatley K, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;7:CD007166.
Thalamas C, Rajman I, Kulisevsky J, Lledó A, Mackie AE, Blin O, et al. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol. 2005;28:120–5.
Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, et al. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol. 2002;161:2209–18.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Tsuboi, T., Watanabe, H., Katsuno, M., Sobue, G. (2020). Pergolide in the Treatment of Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_232-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_232-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine